An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

NCT05592483 · clinicaltrials.gov ↗
TERMINATED
Status
78
Enrollment
INDUSTRY
Sponsor class

Stopped The DESTINY-Breast RESPOND study was terminated early due to start-up delays and slow enrolment, despite extensive mitigation. Operational challenges alone prevent study continuation and were not related to any product or patient safety concerns.

Conditions

Interventions

Sponsor

AstraZeneca